Chapter 19: Problem 3
An unapproved form of gene therapy, known as enhancement gene therapy, can create considerable ethical dilemmas. Why?
Chapter 19: Problem 3
An unapproved form of gene therapy, known as enhancement gene therapy, can create considerable ethical dilemmas. Why?
All the tools & learning materials you need for study success - in one app.
Get started for freeIn March 2010 Judge \(R\). Sweet ruled to invalidate Myriad Genetics' patents on the \(B R C A 1\) and \(B R C A 2\) genes. Sweet wrote that since the genes are part of the natural world, they are not patentable. Myriad Genetics also holds patents on the development of a direct-to-consumer test for the \(B R C A 1\) and \(B R C A 2\) genes. (a) Would you agree with Judge Sweet's ruling to invalidate the patenting of the \(B R C A 1\) and \(B R C A 2\) genes? If you were asked to judge the patenting of the direct-to-consumer test for the BRCA1 and BRCA2 genes, how would you rule? (b) J. Craig Venter has filed a patent application for his "firstever human made life form." This patent is designed to cover the genome of \(M\). genitalium. Would your ruling for Venter's "organism" be different from Judge Sweet's ruling on patenting of the \(B R C A 1\) and \(B R C A 2\) genes?
Sequencing the human genome and the development of microarray technology promise to improve our understanding of normal and abnormal cell behavior. How are microarrays dramatically changing our understanding of complex diseases such as cancer?
In this chapter, we focused on a number of interesting applications of genetic engineering, genomics, and biotechnology. At the same time, we found many opportunities to consider the methods and reasoning by which much of this information was acquired. From the explanations given in the chapter, what answers would you propose to the following fundamental questions: (a) What experimental evidence confirms that we have introduced a useful gene into a transgenic organism and that it performs as we anticipate? (b) How can we use DNA analysis to determine that a human fetus has sickle- cell anemia? (c) How can DNA microarray analysis be used to identify specific genes that are being expressed in a specific tissue? (d) How are GWAS carried out, and what information do they provide? (e) What are some of the technical reasons why gene therapy is difficult to carry out effectively?
The first attempts at gene therapy began in 1990 with the treatment of a young girl with a genetic disorder abbreviated SCID. What does SCID stand for? In the context of SCID, what does ADA stand for?
What limits the use of differences in restriction enzyme sites as a way of detecting point mutations in human genes?
What do you think about this solution?
We value your feedback to improve our textbook solutions.